Previous 10 | Next 10 |
ViewRay, Inc. (VRAY) Q2 2020 Earnings Conference Call July 30, 2020 4:30 PM ET Company Participants Michaella Gallina – Vice President-Chief of Staff and Head-Investor Relations Scott Drake – President and Chief Executive Officer Zach Stassen – Chief Financia...
The following slide deck was published by ViewRay, Inc. in conjunction with their 2020 Q2 earnings Read more ...
For Q2 , ViewRay ( VRAY +11.5% ) reported total revenue of $14.2M, primarily from two revenue units, vs. $30.2M, primarily from five revenue units, year ago quarter; beating consensus by $7.39M. More news on: ViewRay, Inc., Healthcare stocks news, Earnings news and commentary, St...
Image source: The Motley Fool. ViewRay, Inc. (NASDAQ: VRAY) Q2 2020 Earnings Call Jul 30, 2020 , 4:30 p.m. ET Operator Continue reading
ViewRay (NASDAQ: VRAY ) : Q2 GAAP EPS of -$0.18 misses by $0.03 . More news on: ViewRay, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CLEVELAND , July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020 . Second Quarter 2020 Highlights: Total revenue of $14.2 million , primarily from two revenue units, compared to $30.2...
CLEVELAND , July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results. ViewRay will hold a conference call to discuss results on Thursday, July 30, 2020 at 4:30 p.m. ET /...
European Urology Oncology Journal published additional outcome from ViewRay's ( VRAY -4.9% ) prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. More news on: ViewRay, Inc., Healthcare stocks news, Read more ...
CLEVELAND , June 23, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. The publication is a foll...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
News, Short Squeeze, Breakout and More Instantly...
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets PR Newswire DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17 , i...